Compound bronchodilator preparations in COPD (LAMA/LABA) (Formulary)

TAM (Treatments and Medicines) NHS Highland
NHS Highland

Consider combination umeclidinium with vilanterol (Anoro Ellipta®) as first choice in patients with moderate to very severe COPD who are breathless but not prone to exacerbations or not suitable/unwilling to take inhaled corticosteroid. The Spiolto Respimat® and the Duaklir Genuair® offer alternative devices.

UMECLIDINIUM WITH VILANTEROL - (First line)

Therapy notes

Formulation and dosage details

Formulation:

PREFERRED: Dry Powder Inhaler (DPI) (Inhalation powder)These are more environmentally friendly than MDIs and should be considered first line providing that the patient shows good inhaler technique with the chosen device.

  • Dry powder inhaler (Anoro Ellipta®) (umeclidinium 55 micrograms and vilanterol 22 micrograms per dose) 

Dosage:

COPD: by inhalation of powder, 1 puff once daily.

TIOTROPIUM WITH OLODATEROL

Therapy notes

Formulation and dosage details

Formulation:

PREFERRED: Soft Mist Inhaler (SMI)These are more environmentally friendly than MDIs and should be considered first line providing that the patient shows good inhaler technique with the chosen device.

  • Solution for inhalation cartridge (Spiolto Respimat®) (tiotropium 2·5 micrograms and olodaterol 2·5 micrograms per dose)

Dosage:

COPD: by aerosol inhalation, 2 puffs once daily.

ACLIDINIUM WITH FORMOTEROL

Therapy notes

Formulation and dosage details

Formulation:

PREFERRED: Dry Powder Inhaler (DPI) (Inhalation powder)These are more environmentally friendly than MDIs and should be considered first line providing that the patient shows good inhaler technique with the chosen device.

  • Inhalation powder (Duaklir Genuair®) (aclidi nium 340 micrograms and formoterol 12 micrograms per dose) 

Dosage:

COPD: by inhalation of powder, 1 puff twice daily.

Editorial Information

Document Id: F350